Who are FOLFOX or CAPOX adjuvant chemotherapy's main competitors?

No direct comparators detected in our index.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/folfox-or-capox-adjuvant-chemotherapy.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-17 · How we verify

FOLFOX or CAPOX adjuvant chemotherapy — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

FOLFOX or CAPOX adjuvant chemotherapy (FOLFOX or CAPOX adjuvant chemotherapy) competitive landscape: 0 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Platinum-based combination chemotherapy. Area: Oncology.

phase 3 Platinum-based combination chemotherapy DNA (oxaliplatin crosslinking); thymidylate synthase (fluoropyrimidines) Oncology Small molecule Live · refreshed every 30 min

Target snapshot

FOLFOX or CAPOX adjuvant chemotherapy (FOLFOX or CAPOX adjuvant chemotherapy) — Seoul National University Hospital. FOLFOX and CAPOX are combination chemotherapy regimens that use fluorouracil and oxaliplatin to damage cancer cell DNA and inhibit cell division.

Comparator set

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
FOLFOX or CAPOX adjuvant chemotherapy TARGET	FOLFOX or CAPOX adjuvant chemotherapy	Seoul National University Hospital	phase 3	Platinum-based combination chemotherapy	DNA (oxaliplatin crosslinking); thymidylate synthase (fluoropyrimidines)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Platinum-based combination chemotherapy class)

Seoul National University Hospital · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). FOLFOX or CAPOX adjuvant chemotherapy — Competitive Intelligence Brief. https://druglandscape.com/ci/folfox-or-capox-adjuvant-chemotherapy. Accessed 2026-05-17.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab